The FDA appears set to relax restrictions on 14 peptides currently banned, following reports that Robert F. Kennedy Jr. intended to push for such a change. This move comes despite significant internal reservations from top FDA officials who fear decisions are being swayed by politics rather than scientific evidence. Access to these substances is a contentious point in the medical community.

Certain popular compounds are anticipated to be included in the eased access list, such as BPC-157, known for purported tissue repair properties, alongside growth-hormone-releasing agents like CJC-1295 and Ipamorelin. Experts argue that randomized controlled trial data proving efficacy for these substances is nonexistent, making their widespread use a medical gamble for consumers.

Experts cite serious safety risks associated with these compounds, including the danger of impurities from black-market sources and unpredictable dosing in self-administered “stacks.” Growth-stimulating peptides carry specific concerns, potentially spurring cancers or causing hormonal disruptions, as evidenced by recent severe illnesses reported after injections. Eric Topol summarized the situation by calling the current data situation "a mess."

Allowing compounding pharmacies to manufacture these substances removes a key regulatory barrier. The lack of verifiable efficacy data, coupled with documented adverse events, suggests that FDA is prioritizing access over established safety protocols for these unproven treatments.